Desmoteplase

DB04925

biotech investigational

Deskripsi

Desmoteplase is a chemical in the saliva of vampire bats. It activates plasminogen to the serine protease, plasmin. Plasmin acts by breaking down fibrin blood clots. When a vampire bat bites its victim, it secretes an enzyme that prevents the blood from clotting. The enzyme is called DSPA (Desmodus rotundus salivary plasminogen activator) and scientists are using DSPA as stroke and heart attack medication. Desmoteplase is a recombinant form of vampire bat DSPA (Salivary plasminogen activator alpha 1).

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Makanan

1 Data
  • 1. Avoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include garlic, ginger, bilberry, danshen, piracetam, and ginkgo biloba.

Interaksi Obat

642 Data
Apixaban Apixaban may increase the anticoagulant activities of Desmoteplase.
Dabigatran etexilate Dabigatran etexilate may increase the anticoagulant activities of Desmoteplase.
Dasatinib The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Desmoteplase.
Deferasirox The risk or severity of gastrointestinal bleeding can be increased when Desmoteplase is combined with Deferasirox.
Ursodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Desmoteplase is combined with Ursodeoxycholic acid.
Glycochenodeoxycholic Acid The risk or severity of bleeding and bruising can be increased when Desmoteplase is combined with Glycochenodeoxycholic Acid.
Cholic Acid The risk or severity of bleeding and bruising can be increased when Desmoteplase is combined with Cholic Acid.
Glycocholic acid The risk or severity of bleeding and bruising can be increased when Desmoteplase is combined with Glycocholic acid.
Deoxycholic acid The risk or severity of bleeding and bruising can be increased when Desmoteplase is combined with Deoxycholic acid.
Taurocholic acid The risk or severity of bleeding and bruising can be increased when Desmoteplase is combined with Taurocholic acid.
Obeticholic acid The risk or severity of bleeding and bruising can be increased when Desmoteplase is combined with Obeticholic acid.
Chenodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Desmoteplase is combined with Chenodeoxycholic acid.
Taurochenodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Desmoteplase is combined with Taurochenodeoxycholic acid.
Tauroursodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Desmoteplase is combined with Tauroursodeoxycholic acid.
Bamet-UD2 The risk or severity of bleeding and bruising can be increased when Desmoteplase is combined with Bamet-UD2.
Dehydrocholic acid The risk or severity of bleeding and bruising can be increased when Desmoteplase is combined with Dehydrocholic acid.
Hyodeoxycholic Acid The risk or severity of bleeding and bruising can be increased when Desmoteplase is combined with Hyodeoxycholic Acid.
Edoxaban The risk or severity of bleeding can be increased when Edoxaban is combined with Desmoteplase.
Ibrutinib The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Desmoteplase.
Obinutuzumab The risk or severity of bleeding and hemorrhage can be increased when Desmoteplase is combined with Obinutuzumab.
Rivaroxaban Desmoteplase may increase the anticoagulant activities of Rivaroxaban.
Sugammadex The risk or severity of bleeding and hemorrhage can be increased when Desmoteplase is combined with Sugammadex.
Tibolone Tibolone may increase the anticoagulant activities of Desmoteplase.
Tipranavir The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Desmoteplase.
Urokinase Urokinase may increase the anticoagulant activities of Desmoteplase.
Vitamin E Vitamin E may increase the anticoagulant activities of Desmoteplase.
Vorapaxar The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with Desmoteplase.
Aprotinin The therapeutic efficacy of Desmoteplase can be decreased when used in combination with Aprotinin.
Ginkgo biloba Ginkgo biloba may increase the anticoagulant activities of Desmoteplase.
Ifosfamide The risk or severity of bleeding can be increased when Ifosfamide is combined with Desmoteplase.
Quinine The therapeutic efficacy of Desmoteplase can be increased when used in combination with Quinine.
Quinidine The therapeutic efficacy of Desmoteplase can be increased when used in combination with Quinidine.
Tamoxifen The risk or severity of bleeding can be increased when Tamoxifen is combined with Desmoteplase.
Toremifene The risk or severity of bleeding can be increased when Toremifene is combined with Desmoteplase.
Pentoxifylline The therapeutic efficacy of Desmoteplase can be increased when used in combination with Pentoxifylline.
Pentosan polysulfate Pentosan polysulfate may increase the anticoagulant activities of Desmoteplase.
Levocarnitine The therapeutic efficacy of Desmoteplase can be increased when used in combination with Levocarnitine.
Diethylstilbestrol Diethylstilbestrol may decrease the anticoagulant activities of Desmoteplase.
Chlorotrianisene Chlorotrianisene may decrease the anticoagulant activities of Desmoteplase.
Conjugated estrogens Conjugated estrogens may decrease the anticoagulant activities of Desmoteplase.
Mestranol The risk or severity of adverse effects can be increased when Mestranol is combined with Desmoteplase.
Estrone sulfate Estrone sulfate may decrease the anticoagulant activities of Desmoteplase.
Quinestrol Quinestrol may decrease the anticoagulant activities of Desmoteplase.
Hexestrol Hexestrol may decrease the anticoagulant activities of Desmoteplase.
Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Desmoteplase.
Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Desmoteplase.
Polyestradiol phosphate Polyestradiol phosphate may decrease the anticoagulant activities of Desmoteplase.
Esterified estrogens Esterified estrogens may decrease the anticoagulant activities of Desmoteplase.
Zeranol Zeranol may decrease the anticoagulant activities of Desmoteplase.
Equol Equol may decrease the anticoagulant activities of Desmoteplase.
Methallenestril Methallenestril may decrease the anticoagulant activities of Desmoteplase.
Epimestrol Epimestrol may decrease the anticoagulant activities of Desmoteplase.
Moxestrol Moxestrol may decrease the anticoagulant activities of Desmoteplase.
Estradiol acetate Estradiol acetate may decrease the anticoagulant activities of Desmoteplase.
Estradiol benzoate Estradiol benzoate may decrease the anticoagulant activities of Desmoteplase.
Estradiol cypionate Estradiol cypionate may decrease the anticoagulant activities of Desmoteplase.
Estradiol valerate Estradiol valerate may decrease the anticoagulant activities of Desmoteplase.
Biochanin A Biochanin A may decrease the anticoagulant activities of Desmoteplase.
Formononetin Formononetin may decrease the anticoagulant activities of Desmoteplase.
Estriol Estriol may decrease the anticoagulant activities of Desmoteplase.
Icosapent The risk or severity of bleeding and hemorrhage can be increased when Icosapent is combined with Desmoteplase.
Mesalazine The risk or severity of bleeding can be increased when Mesalazine is combined with Desmoteplase.
Indomethacin The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Desmoteplase.
Nabumetone The risk or severity of bleeding and hemorrhage can be increased when Nabumetone is combined with Desmoteplase.
Ketorolac The risk or severity of bleeding and hemorrhage can be increased when Ketorolac is combined with Desmoteplase.
Tenoxicam The risk or severity of bleeding and hemorrhage can be increased when Tenoxicam is combined with Desmoteplase.
Celecoxib The risk or severity of bleeding and hemorrhage can be increased when Celecoxib is combined with Desmoteplase.
Tolmetin The risk or severity of bleeding and hemorrhage can be increased when Tolmetin is combined with Desmoteplase.
Rofecoxib The risk or severity of bleeding and hemorrhage can be increased when Rofecoxib is combined with Desmoteplase.
Piroxicam The risk or severity of bleeding and hemorrhage can be increased when Piroxicam is combined with Desmoteplase.
Fenoprofen The risk or severity of bleeding and hemorrhage can be increased when Fenoprofen is combined with Desmoteplase.
Valdecoxib The risk or severity of bleeding and hemorrhage can be increased when Valdecoxib is combined with Desmoteplase.
Diclofenac The risk or severity of bleeding and hemorrhage can be increased when Diclofenac is combined with Desmoteplase.
Sulindac The risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Desmoteplase.
Flurbiprofen The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen is combined with Desmoteplase.
Etodolac The risk or severity of bleeding and hemorrhage can be increased when Etodolac is combined with Desmoteplase.
Mefenamic acid The risk or severity of bleeding and hemorrhage can be increased when Mefenamic acid is combined with Desmoteplase.
Naproxen The risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Desmoteplase.
Sulfasalazine The risk or severity of bleeding and hemorrhage can be increased when Sulfasalazine is combined with Desmoteplase.
Phenylbutazone The risk or severity of bleeding and hemorrhage can be increased when Phenylbutazone is combined with Desmoteplase.
Meloxicam The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Desmoteplase.
Carprofen The risk or severity of bleeding and hemorrhage can be increased when Carprofen is combined with Desmoteplase.
Diflunisal The risk or severity of bleeding and hemorrhage can be increased when Diflunisal is combined with Desmoteplase.
Salicylic acid The risk or severity of bleeding and hemorrhage can be increased when Salicylic acid is combined with Desmoteplase.
Meclofenamic acid The risk or severity of bleeding and hemorrhage can be increased when Meclofenamic acid is combined with Desmoteplase.
Oxaprozin The risk or severity of bleeding and hemorrhage can be increased when Oxaprozin is combined with Desmoteplase.
Ketoprofen The risk or severity of bleeding and hemorrhage can be increased when Ketoprofen is combined with Desmoteplase.
Balsalazide The risk or severity of bleeding and hemorrhage can be increased when Balsalazide is combined with Desmoteplase.
Olsalazine The risk or severity of bleeding can be increased when Olsalazine is combined with Desmoteplase.
Lumiracoxib The risk or severity of bleeding and hemorrhage can be increased when Lumiracoxib is combined with Desmoteplase.
Magnesium salicylate The risk or severity of bleeding and hemorrhage can be increased when Magnesium salicylate is combined with Desmoteplase.
Salsalate The risk or severity of bleeding and hemorrhage can be increased when Salsalate is combined with Desmoteplase.
Choline magnesium trisalicylate The risk or severity of bleeding and hemorrhage can be increased when Choline magnesium trisalicylate is combined with Desmoteplase.
Antrafenine The risk or severity of bleeding and hemorrhage can be increased when Antrafenine is combined with Desmoteplase.
Aminophenazone The risk or severity of bleeding and hemorrhage can be increased when Aminophenazone is combined with Desmoteplase.
Antipyrine The risk or severity of bleeding and hemorrhage can be increased when Antipyrine is combined with Desmoteplase.
Tiaprofenic acid The risk or severity of bleeding and hemorrhage can be increased when Tiaprofenic acid is combined with Desmoteplase.
Etoricoxib The risk or severity of bleeding and hemorrhage can be increased when Etoricoxib is combined with Desmoteplase.
Taxifolin The risk or severity of bleeding and hemorrhage can be increased when Taxifolin is combined with Desmoteplase.
Oxyphenbutazone The risk or severity of bleeding and hemorrhage can be increased when Oxyphenbutazone is combined with Desmoteplase.

Target Protein

Plasminogen PLG

Referensi & Sumber

Artikel (PubMed)
  • PMID: 15529064
    Grandjean C, McMullen PC, Newschwander G: Vampire bats yield potent clot buster for ischemic stroke. J Cardiovasc Nurs. 2004 Nov-Dec;19(6):417-20.
  • PMID: 15569863
    Hacke W, Albers G, Al-Rawi Y, Bogousslavsky J, Davalos A, Eliasziw M, Fischer M, Furlan A, Kaste M, Lees KR, Soehngen M, Warach S: The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke. 2005 Jan;36(1):66-73. Epub 2004 Nov 29.
  • PMID: 11910176
    Schleuning WD: Vampire bat plasminogen activator DSPA-alpha-1 (desmoteplase): a thrombolytic drug optimized by natural selection. Haemostasis. 2001 May-Dec;31(3-6):118-22.
  • PMID: 12574572
    Liberatore GT, Samson A, Bladin C, Schleuning WD, Medcalf RL: Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration. Stroke. 2003 Feb;34(2):537-43.
  • PMID: 15879331
    Reddrop C, Moldrich RX, Beart PM, Farso M, Liberatore GT, Howells DW, Petersen KU, Schleuning WD, Medcalf RL: Vampire bat salivary plasminogen activator (desmoteplase) inhibits tissue-type plasminogen activator-induced potentiation of excitotoxic injury. Stroke. 2005 Jun;36(6):1241-6. Epub 2005 May 5.
  • PMID: 16133891
    Hoffmann JJ, Kops O: Inhibition of desmoteplase-induced fibrinolytic activity in vitro. J Thromb Thrombolysis. 2005 Aug;20(1):23-6.
  • PMID: 16574922
    Furlan AJ, Eyding D, Albers GW, Al-Rawi Y, Lees KR, Rowley HA, Sachara C, Soehngen M, Warach S, Hacke W: Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke. 2006 May;37(5):1227-31. Epub 2006 Mar 30.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul